News note: A new clinical trial evaluates the SpydrBlade Flex device in a POEM procedure for Achalasia and EGJ Outflow Obstruction, signaling a potential regulatory data milestone for this device. Publication date context: February 15, 2026. The trial listing identifies Achalasia and EGJ Outflow Obstruction as the conditions and lists the intervention as device SpydrBlade Flex. Sponsorship is provided by Chinese University of Hong Kong and an academy tertiary center IECED in Guayaquil Ecuador with recruitment currently indicated. The information comes from ClinicalTrials.gov and is used to inform regulators and industry watchers about ongoing evaluation of this novel device.
What is the SpydrBlade Flex trial in POEM?
The source text states that the trial tests a SpydrBlade Flex device in a POEM procedure. It lists Achalasia and EGJ Outflow Obstruction as the targeted conditions and identifies the intervention as Device SpydrBlade Flex. The sponsor is Chinese University of Hong Kong and an academy tertiary center IECED in Guayaquil Ecuador. Recruitment status is shown as Recruiting on ClinicalTrials.gov with the identifier NCT07406945.
What is SpydrBlade Flex?
The device is described as a flexible bipolar instrument used in the POEM procedure. The name SpydrBlade Flex suggests a flexible form factor intended for endoscopic use in this setting.
What conditions are targeted by this trial?
The listing specifies Achalasia and EGJ Outflow Obstruction as the conditions of interest for this study.
Why is POEM used in this context?
POEM stands for Peroral Endoscopic Myotomy and is referenced here as the procedural context for evaluating SpydrBlade Flex.
Who sponsors the trial and where is it conducted?
The trial sponsor is listed as Chinese University of Hong Kong. A second site is indicated in Guayaquil where IECED is described as a tertiary center. The listing also notes that the trial is Recruiting.
What are the regulatory implications and safety considerations?
This trial represents a regulatory relevant activity for a novel device in a POEM setting. The source text does not provide results but implies that safety and performance data will be of interest to regulators. Observers will look for standard trial conduct and adherence to applicable device regulatory expectations.
What happens next and how can updates be followed?
Updates will come from ClinicalTrials.gov and the sponsor communications. The NCT07406945 listing remains the primary source for recruitment status and site details.
FAQ
- What is SpydrBlade Flex used for in this trial Yes the device is tested in a POEM procedure for Achalasia and EGJ Outflow Obstruction.
- Who sponsors the trial Chinese University of Hong Kong and an academy tertiary center IECED in Guayaquil Ecuador are listed as sponsors.
- Where can I find more information The ClinicalTrials.gov listing is NCT07406945 and the provided link is in this article.
- Is the trial recruiting Yes the listing shows Recruiting status.
Conclusion and implications
Readers should monitor the ClinicalTrials.gov listing for updates on recruitment and results. Regulators will evaluate the data as it becomes available and will consider safety and performance in a POEM setting.
This article is intended for professional audiences. It is not legal advice. For legal or regulatory decisions obtain appropriate counsel and consult the official regulatory guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07406945?term=medical+device